Monte Rosa Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
6analysts covering
FY EPS (est.)
-$1.57next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| GFORCE-1 Trial Readout (MRT-8102) | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly671MTarget: Sufficient to fund operations into 2029
MRT-8102 C-Reactive Protein (CRP) Reduction Annually0.9Target: Maintain profound reduction in Phase 2 trials
Watch Items
- Novartis Phase 2 Initiation of MRT-6160Trigger: First patient dosed in Phase 2 clinical trialsAction: Monitor for milestone payment recognition and pipeline validation
- MRT-8102 GFORCE-1 Trial ReadoutTrigger: Topline data release in H2 2026Action: Evaluate safety, tolerability, and CRP reduction efficacy to support ongoing Phase 2 planning
- MRT-2359 Phase 2 MODeFIRe-1 InitiationTrigger: Trial initiation in Q3 2026Action: Track patient enrollment and combination safety with apalutamide
Research as of 19 Jun 2026